REGENXBIO Highlights AAV Pipeline with Interim Results from

-Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of...

Related Keywords

Hawaii , United States , Hawaiian , American , Chris Brinzey , World Muscle Society , Technology Platform , World Muscle Society Congress , Securities Exchange , Exchange Commission , Technology Platform Licensees , Duchenne Program , Retinal Program , American Academy Of Ophthalmology , Manufacturing Innovation Center , Nasdaq , Exon Skipping Program , Virtual Investor Day , Investor Day , Chief Executive Officer , Hawaiian Eye , American Academy , Duchenne Muscular Dystrophy , Investigational New Drug , Platform Licensees , Securities Act , Securities Exchange Act , Financial Condition , Regenxbio Inc , Health Care Amp Hospitals , Biotechnology , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries , Trade Show News ,